MedTrace Logo

Effect of Combination Therapy on SCLC After Initial Treatment Failure

NCT04790955 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2021-03-10

No results posted yet for this study

Summary

SCLC patients after initial treatment failure are treated with SBRT and low-dose radiotherapy concurrent with PARP inhibitors + temozolomide +PD-1/PD-L1 inhibitors for two cycles at least, then PARP inhibitors+temozolomide+PD-1/PD-L1 inhibitors two cycles, PD-1/PD-L1 inhibitors maintenance therapy lasted for up to 2 years.

Conditions

  • Small-cell Lung Cancer

Sponsors & Collaborators

  • First Affiliated Hospital of Harbin Medical University

    lead OTHER

Principal Investigators

  • Daxin Zhang, Dr. · First Affiliated Hospital of Harbin Medical University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2024-03-01
Completion
2024-03-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04790955 on ClinicalTrials.gov